Wolfgang C. Winkelmayer

Wolfgang C. Winkelmayer

Auto-generated profile, based on publicly available information

Wolfgang C. Winkelmayer

Department of Medicine, Section of Nephrology, Baylor College of Medicine, Houston, Texas

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
WWWolfgang C. Winkelmayer
Wolfgang C. Winkelmayer
JLJun Liu
Jun Liu
SSSoko Setoguchi
Soko Setoguchi
NCNiteesh K. Choudhry
Niteesh K. Choudhry
Summary: Background and objectives: Although generally recommended in atrial fibrillation (AF) patients, the effectiveness and safety of oral anticoagulation in dialysis patients with AF is unknown. Design, setting, participants, & measurements: We assembled a cohort of older hemodialysis patients who initiated dialysis without prior record of AF and who had prescription drug benefits through three state-administered programs. The index event was a first hospitalization with diagnosed AF; patients with any recorded prior warfarin use were excluded. Eligible patients survived ≥30 days from discharge, and new warfarin use was recorded from prescription records during that 30-day window. Propensity-matched warfarin users and nonusers were compared using Cox regression. Outcomes included ischemic stroke, hemorrhagic stroke, and mortality. Results: Among 2313 patients with new AF who survived 30 days from discharge, 249 (10.8%) filled a prescription for warfarin. Comparing 237 warfarin users and 948 propensity-matched nonusers over 2287 person-years of follow-up, the occurrence of ischemic stroke was similar (HR = 0.92; 95% CI, 0.61 to 1.37), whereas warfarin users experienced twice the risk of hemorrhagic stroke (HR = 2.38; 95% CI, 1.15 to 4.96). The risks of stroke, gastrointestinal hemorrhage, and mortality did not differ between groups. As-treated analyses yielded similar findings, as did analyses restricted to patients with CHADS2 scores ≥2. Conclusions: Although we confirmed association between warfarin use and hemorrhagic stroke in dialysis patients with AF, we found no association between warfarin use and ischemic stroke. Adequately powered randomized trials are required to conclusively determine the risks and benefits of the studied warfarin indication in hemodialysis patients.

1 February 2011 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
WWWolfgang C. Winkelmayer
Wolfgang C. Winkelmayer
APAmanda R. Patrick
Amanda R. Patrick
JLJun Liu
Jun Liu
MBM. Alan Brookhart
M. Alan Brookhart
SSSoko Setoguchi
Soko Setoguchi
A half million Americans have ESRD, which puts them at high risk for cardiovascular disease and poor outcomes. Little is known about the epidemiology of atrial fibrillation among patients with ESRD. We analyzed data from annual cohorts (1992 to 2006) of prevalent hemodialysis patients from the United States Renal Data System. In each cohort, we searched 1 year of medical claims for relevant diagnosis codes to determine the prevalence of atrial fibrillation. Among 2.5 million patient observations, 7.7% had atrial fibrillation, with the prevalence increasing 3-fold from 3.5% (1992) to 10.7% (2006). The number of affected patients increased from 3620 to 23,893 (6.6-fold) during this period. Older age, male gender, and several comorbid conditions were associated with increased risk for atrial fibrillation. Compared with otherwise similar Caucasians, the prevalence of atrial fibrillation rates was substantially lower for blacks, Asians, and Native Americans. One-year mortality was twice as high among hemodialysis patients with atrial fibrillation compared with those without (39% versus 19%), and this increased risk was constant during the 15 years of the study. In conclusion, the prevalence of diagnosed atrial fibrillation among patients receiving hemodialysis in the United States is increasing, varies by race, and remains associated with substantially increased mortality. Identifying potentially modifiable risk factors for incident atrial fibrillation requires further investigation.

1 February 2019 in Kidney International
Verified
Journal Article
Open access
JFJürgen Floege
Jürgen Floege
SBSean J. Barbour
Sean J. Barbour
DCDaniel C. Cattran
Daniel C. Cattran
JHJonathan J. Hogan
Jonathan J. Hogan
PNPatrick H. Nachman
Patrick H. Nachman
SWScott E. Wenderfer
Scott E. Wenderfer
The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. The conference focused on the 2012 KDIGO guideline with the aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, in particular, therapy of glomerular diseases since the guideline's publication. It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy.

9 November 2005 in JAMA
Verified
Journal Article
Open access
PDF file
WWWolfgang C. Winkelmayer
Wolfgang C. Winkelmayer
MSMeir J. Stampfer
Meir J. Stampfer
WWWalter C. Willett
Walter C. Willett
GCGary C. Curhan
Gary C. Curhan
Approximately 50 million people in the United States have hypertension, and the prevalence is increasing.1 Hypertension is a major risk factor for coronary heart disease, stroke, and congestive heart failure.2,3 Therefore, even small reductions in the prevalence of hypertension could have a potentially large public health and financial impact.

23 November 2018 in American Journal of Nephrology
Verified
Journal Article
Closed access
PDF file
AAAhmed A. Awan
Ahmed A. Awan
JNJingbo Niu
Jingbo Niu
JPJenny S. Pan
Jenny S. Pan
KEKevin F. Erickson
Kevin F. Erickson
SMSreedhar Mandayam
Sreedhar Mandayam
VRVenkat Ramanathan
Venkat Ramanathan
Background: Death with graft function remains an important cause of graft loss among kidney transplant recipients (KTRs). Little is known about the trend of specific causes of death in KTRs in recent years. Methods: We analyzed United States Renal Data System data (1996–2014) to determine 1- and 10-year all-cause and cause-specific mortality in adult KTRs who died with a functioning allograft. We also studied 1- and 10-year trends in the various causes of mortality. Results: Of 210,327 KTRs who received their first kidney transplant from 1996 to 2014, 3.2% died within 1 year after transplant. Cardiovascular deaths constituted the majority (24.7%), followed by infectious (15.2%) and malignant (2.9%) causes; 40.1% of deaths had no reported cause. Using 1996 as the referent year, all-cause as well as cardiovascular mortality declined, whereas mortality due to malignancy did not. For analyses of 10-year mortality, we studied 94,384 patients who received a first kidney transplant from 1996 to 2005. Of those, 22.1% died over 10 years and the causative patterns of their causes of death were similar to those associated with 1-year mortality. Conclusions: Despite the downtrend in mortality over the last 2 decades, a significant percentage of KTRs die in 10-years with a functioning graft, and cardiovascular mortality remains the leading cause of death. These data also highlight the need for diligent collection of mortality data in KTRs.

1 August 2005 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
WWWolfgang C. Winkelmayer
Wolfgang C. Winkelmayer
SSSebastian Schneeweiss
Sebastian Schneeweiss
HMHelen Mogun
Helen Mogun
APAmanda R. Patrick
Amanda R. Patrick
JAJerry Avorn
Jerry Avorn
DSDaniel H. Solomon
Daniel H. Solomon